Literature DB >> 24457634

HIV infection and its association with an excess risk of clinical fractures: a nationwide case-control study.

Daniel Prieto-Alhambra1, Robert Güerri-Fernández, Frank De Vries, Arief Lalmohamed, Marloes Bazelier, Jakob Starup-Linde, Adolfo Diez-Perez, Cyrus Cooper, Peter Vestergaard.   

Abstract

BACKGROUND: Different studies have reported an association between HIV infection, antiretroviral therapies, and impaired bone metabolism, but data on their impact on fracture risk are scarce. We studied the association between a clinical diagnosis of HIV infection and fracture risk.
METHODS: We conducted a case-control study using data from the Danish National Health Service registries, including 124,655 fracture cases and 373,962 age- and gender-matched controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression.
RESULTS: A total of 50 (0.40/1000) patients in the fracture group and 52 (0.14/1000) controls had an HIV diagnosis. The risk of any fracture was thus significantly increased among HIV-infected patients (age- and gender-matched OR = 2.89, 95% CI: 1.99 to 4.18). Similarly, significant increases in the risk of hip (OR = 8.99, 95% CI: 1.39 to 58.0), forearm (OR = 3.50, 95% CI: 1.26 to 9.72), and spine fractures (OR = 9.00, 95% CI: 1.39 to 58.1) were observed.
CONCLUSIONS: HIV infection is associated with an almost 3-fold increase in fracture risk compared with that of age- and gender-matched uninfected patients. HIV patients are also at an almost 9-fold higher risk of hip fracture.

Entities:  

Mesh:

Year:  2014        PMID: 24457634     DOI: 10.1097/QAI.0000000000000112

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  29 in total

1.  Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults.

Authors:  Philip M Grant; Douglas Kitch; Grace A McComsey; Camlin Tierney; Belinda Ha; Todd T Brown
Journal:  HIV Clin Trials       Date:  2015-04-15

Review 2.  The protease inhibitors and HIV-associated bone loss.

Authors:  Caitlin A Moran; M Neale Weitzmann; Ighovwerha Ofotokun
Journal:  Curr Opin HIV AIDS       Date:  2016-05       Impact factor: 4.283

3.  An observational case series of HIV-positive patients treated with open reduction internal fixation for a closed lower extremity fracture.

Authors:  Jiandong Hao; Benoit Herbert; Juan C Quispe; Derly O Cuellar; Vivek Chadayammuri; Ji Wan Kim; Heather Young; Mark E Hake; Mark E Hammerberg; David J Hak; Cyril Mauffrey
Journal:  Eur J Orthop Surg Traumatol       Date:  2015-02-04

4.  Inflammation status in HIV-positive individuals correlates with changes in bone tissue quality after initiation of ART.

Authors:  E Lerma-Chippirraz; Marta Pineda-Moncusí; A González-Mena; Jade Soldado-Folgado; H Knobel; M Trenchs-Rodríguez; A Díez-Pérez; Todd T Brown; N García-Giralt; R Güerri-Fernández
Journal:  J Antimicrob Chemother       Date:  2019-05-01       Impact factor: 5.790

Review 5.  Complications of Treatment in Youth with HIV.

Authors:  Allison Ross Eckard; Sandra L Fowler; Julia C Haston; Terry C Dixon
Journal:  Curr HIV/AIDS Rep       Date:  2016-08       Impact factor: 5.071

6.  Deciphering how HIV-1 weakens and cracks the bone.

Authors:  Ighovwerha Ofotokun
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-01       Impact factor: 11.205

Review 7.  Bone health in HIV and hepatitis B or C infections.

Authors:  Emmanuel Biver; Alexandra Calmy; René Rizzoli
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-10-07       Impact factor: 5.346

8.  Plasma Sclerostin in HIV-Infected Adults on Effective Antiretroviral Therapy.

Authors:  Kristine M Erlandson; MaryAnn O'Riordan; Corrilynn O Hileman; Eric Rapaport; Danielle Labbato; Thomas B Campbell; Grace A McComsey
Journal:  AIDS Res Hum Retroviruses       Date:  2015-05-27       Impact factor: 2.205

9.  A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial.

Authors:  Ighovwerha Ofotokun; Kehmia Titanji; Cecile D Lahiri; Aswani Vunnava; Antonina Foster; Sara E Sanford; Anandi N Sheth; Jeffrey L Lennox; Andrea Knezevic; Laura Ward; Kirk A Easley; Philip Powers; M Neale Weitzmann
Journal:  Clin Infect Dis       Date:  2016-05-18       Impact factor: 9.079

10.  Increased Fracture Incidence in Middle-Aged HIV-Infected and HIV-Uninfected Women: Updated Results From the Women's Interagency HIV Study.

Authors:  Anjali Sharma; Qiuhu Shi; Donald R Hoover; Kathryn Anastos; Phyllis C Tien; Mary A Young; Mardge H Cohen; Elizabeth T Golub; Deborah Gustafson; Michael T Yin
Journal:  J Acquir Immune Defic Syndr       Date:  2015-09-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.